Electronic Theses and Dissertation

Kanker prostat merupakan kanker terbanyak kedua pada pria, dan sering disertai nyeri neuropatik akibat metastasis tulang atau terapi kanker. pregabalin dikenal sebagai terapi lini pertama untuk nyeri neuropatik, namun potensi perannya dalam memodulasi proliferasi sel kanker masih jarang diteliti. penelitian ini bertujuan untuk mengetahui efek pregabalin terhadap proliferasi sel kanker prostat pc3 secara in vitro melalui ekspresi protein ki67 dan viabilitas sel. penelitian dilakukan secara eksperimental in vitro dengan rancangan acak lengkap. sel kanker prostat pc3 dikultur dalam media ham's f12, lalu diberikan pregabalin pada konsentrasi 8.000 ng/ml, 16.000 ng/ml, 32.000 ng/ml, dan 64.000 ng/ml, masing-masing dengan tiga replikasi pada dua waktu inkubasi: 48 jam dan 72 jam. proliferasi sel diukur menggunakan ekspresi protein ki67 melalui metode elisa, sedangkan viabilitas sel dianalisis dengan uji mtt. data dianalisis dengan anova satu arah dan uji lanjut post hoc pada α = 0,05. hasil menunjukkan perbedaan bermakna ekspresi ki67 antara kelompok kontrol dan perlakuan (p = 0,000), dengan dosis 32.000 ng/ml paling efektif menghambat proliferasi pada 72 jam. namun, pada 48 jam tidak ditemukan perbedaan bermakna baik pada ekspresi ki67 maupun viabilitas sel. hasil ini mengindikasikan bahwa pregabalin dapat memiliki efek antiproliferatif terhadap sel kanker prostat, tergantung pada dosis dan durasi paparan. temuan ini membuka kemungkinan penggunaan pregabalin tidak hanya sebagai analgesik, tetapi juga sebagai agen tambahan potensial dalam terapi kanker.

Prostate cancer ranks as the second most common malignancy among men and is frequently associated with neuropathic pain due to bone metastases or cancer therapies. Pregabalin is a first-line treatment for neuropathic pain, but its potential role in modulating cancer cell proliferation remains underexplored. This study aimed to evaluate the effect of pregabalin on the proliferation of PC3 prostate cancer cells in vitro by assessing Ki67 protein expression and cell viability. An in vitro experimental study with a completely randomized design was conducted. PC3 cells were cultured in Ham’s F12 medium and treated with pregabalin at concentrations of 8,000 ng/ml, 16,000 ng/ml, 32,000 ng/ml, and 64,000 ng/ml, each with three replicates at two incubation periods: 48 hours and 72 hours. Cell proliferation was evaluated using Ki67 protein expression via ELISA, and cell viability was assessed through the MTT assay. Data were analyzed using one-way ANOVA and post hoc testing at a 0.05 significance level. The results showed a significant difference in Ki67 expression between control and treatment groups (p = 0.000), with 32,000 ng/ml being the most effective dose in inhibiting proliferation at 72 hours. However, no significant effects were observed in either Ki67 expression or cell viability at 48 hours. These findings suggest that pregabalin may exhibit anti-proliferative effects on prostate cancer cells with sufficient exposure time and appropriate dosing, indicating its potential role beyond analgesia as an adjunctive therapeutic agent in cancer treatment.